L19IL2

Summary

L19Il2 (CHEMBL2109608) is a phase-3 clinical-stage unknown; indicated across 4 conditions including melanoma and metastatic melanoma; with CIViC clinical evidence for 2 variant-indication associations (e.g. FN1 EDB in melanoma).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 11
• Precision-oncology evidence (CIViC): 2 variant–indication associations

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109608
Name	L19IL2
Type	Unknown
Max phase	3

Also known as: L19il2, L19IL2

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
melanoma	3	MONDO:0005105	EFO:0000756
metastatic melanoma	3	MONDO:0005191	EFO:0002617
neoplasm	1	MONDO:0005070	EFO:0000616
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	7
PHASE1	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02938299	PHASE3	ACTIVE_NOT_RECRUITING	Neoadjuvant L19IL2/L19TNF- Pivotal Study
NCT06284590	PHASE2	RECRUITING	Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
NCT07227350	PHASE2	NOT_YET_RECRUITING	L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
NCT07227870	PHASE2	NOT_YET_RECRUITING	L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07228442	PHASE2	NOT_YET_RECRUITING	L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT01058538	PHASE1/PHASE2	COMPLETED	A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
NCT02076633	PHASE2	COMPLETED	Intratumoral Administration of L19IL2/L19TNF
NCT04362722	PHASE2	UNKNOWN	Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
NCT05329792	PHASE2	UNKNOWN	L19IL2/L19TNF in Skin Cancer Patients
NCT06640413	PHASE1	RECRUITING	A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
NCT07566897	PHASE1	NOT_YET_RECRUITING	A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

Clinical evidence (CIViC)

Variant × indication × effect (2 predictive associations from 2 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
FN1 EDB	Melanoma	Sensitivity/Response	L19IL2 + Dacarbazine	CIViC B	EID9625
FN1 EDB	Melanoma	Sensitivity/Response	L19IL2	CIViC B	EID9626

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).